Genextra Spa - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
37
About the Report
About the Report
Summary
Genextra SpA (Genextra) is a therapies developing company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, INT- 777 for metabolic syndrome, mono therapy and diabetes, novel HDAC and HSP90 inhibitors for the treatment of cancer. It also provides mjPTP inhibitor and nanoparticles in gas phase to yields, among others. Genextra provides research in life science and to develop novel therapies and tools, among others. The company caters to entrepreneurs and financial institutions in partnership with leading scientists, among others. It operates through its subsidiaries located across Italy. Genextra is headquartered in Milan, Italy.
Genextra Spa-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Genextra Spa, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Genextra Spa, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
EryDel Raises USD32.4 Million in Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 11
EryDel Raises USD 20 Million In Series B Financing 12
Intercept Pharma Raises USD 30 Million In Series C Financing 13
Partnerships 15
Intercept Pharma Extends Agreement with Target Pharma 15
Intercept Pharma Enters into Research Agreement with University of Perugia 16
Licensing Agreements 17
EryDel and Orphan Technologies Enter into Licensing Agreement 17
Equity Offering 18
Intercept Pharma Prices Private Placement of Shares for USD100 Million 18
Intercept Pharma Prices Public Offering of Shares for USD150 Million 20
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 22
Intercept Pharma Raises USD202 Million in Public Offering of Shares 24
Intercept Pharma Completes Public Offering Of Shares For USD 192 Million 26
Intercept Pharma Completes Public Offering Of Shares For USD 65.7 Million 28
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 86 Million 30
Debt Offering 32
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 32
Genextra Spa-Key Competitors 34
Genextra Spa-Key Employees 35
Genextra Spa-Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Figure
List of Figures
Genextra Spa, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Genextra Spa, Pharmaceuticals & Healthcare, Key Facts 2
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genextra Spa, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genextra Spa, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genextra Spa, Deals By Therapy Area, 2012 to YTD 2018 8
Genextra Spa, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
EryDel Raises USD32.4 Million in Venture Financing 10
EryDel Raises Additional USD16.23 million in Series B Financing 11
EryDel Raises USD 20 Million In Series B Financing 12
Intercept Pharma Raises USD 30 Million In Series C Financing 13
Intercept Pharma Extends Agreement with Target Pharma 15
Intercept Pharma Enters into Research Agreement with University of Perugia 16
EryDel and Orphan Technologies Enter into Licensing Agreement 17
Intercept Pharma Prices Private Placement of Shares for USD100 Million 18
Intercept Pharma Prices Public Offering of Shares for USD150 Million 20
Intercept Pharma Raises USD367.3 Million in Public Offering of Shares 22
Intercept Pharma Raises USD202 Million in Public Offering of Shares 24
Intercept Pharma Completes Public Offering Of Shares For USD 192 Million 26
Intercept Pharma Completes Public Offering Of Shares For USD 65.7 Million 28
Intercept Pharma Completes Underwriters' Exercise Of Over-Allotment Option For USD 86 Million 30
Intercept Pharma Raises USD460 Million in Public Offering of 3.25% Notes Due 2023 32
Genextra Spa, Key Competitors 34
Genextra Spa, Key Employees 35
Genextra Spa, Subsidiaries 36
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.